Skip to main content
SpringerLink
Log in

Inhibition of neurogenic inflammation in abortive migraine treatment

  • Chapter
Migraine: A Neuroinflammatory Disease?

Part of the book series: Progress in Inflammation Research ((PIR))

  • 78 Accesses

Abstract

Neurogenic inflammation is mediated through the release of peptides, called neuropeptides, from the sensory nerve fibers involved in nociception. It comprises two processes, plasma-protein extravasation and neurogenic vasodilation, mediated predominantly by substance P and calcitonin gene-related peptide, respectively. Substance P is released from the unmyelinated C fibers and opens up post-capillary venules by acting on neurokinin-1 receptors, allowing the extravasation of plasma proteins. Calcitonin gene-related peptide, on the other hand, is released from the small myelinated Aθ fibers and dilates the arterioles by stimulating receptors of its own.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chapman LF, Ramos AO, Goodell H et al (1960) A humoral agent implicated in vas-cular headache of the migraine type. Arch Neurol 3: 223–229

    Article  PubMed  CAS  Google Scholar 

  2. Graham JR, Wolff HG (1938) Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiat 39: 737–763

    Article  CAS  Google Scholar 

  3. Spierings ELH (2000) The (suma)triptan history revisited (letter). Headache 40:766–767

    Article  PubMed  CAS  Google Scholar 

  4. Buzzie MG, Moskowitz MA (1990) The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99: 202–206

    Article  Google Scholar 

  5. Earl NL, McDonald SA, Lowy MT (1999) Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine (abstract). Cephalalgia 19: 357

    Google Scholar 

  6. Manilla BG, Cutler N, Leibowitz MT et al (2001) Safety and efficacy of PNU-142633 a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia; in press

    Google Scholar 

  7. Johnson KW, Schaus JM, Durkin MM et al (1997) 5-HT1F receptor agonists inhibit neurogenic durai inflammation in guinea pigs. Neuroreport 8: 2237–2240

    Article  PubMed  CAS  Google Scholar 

  8. Shepheard S, Edvinsson L, Cumberbatch M et al (1999) Possible antimigraine mecha-nisms of action of the 5HTIF receptor agonist LY334370. Cephalalgia 19: 851–858

    Article  PubMed  CAS  Google Scholar 

  9. Goldstein DJ, Roon KI, Offen WW et al (1999) Migraine treatment with selective 5-HT1F receptor agonist (SSOFRA) LY334370 (abstract). Cephalalgia 19: 318

    Google Scholar 

  10. Lee WS, Moskowitz MA (1993) Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638, exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res 626: 303–305

    Article  PubMed  CAS  Google Scholar 

  11. Gupta P, Brown D, Butler P et al (1995) The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation. Br J Pharmacol 116: 2385–2390

    Article  PubMed  CAS  Google Scholar 

  12. Shepheard SL, Williamson DJ, Beer MS et al (1997) Differential effects of 5-HT1B/1D receptor agonists on neurogenic durai plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 36: 525–533

    Article  Google Scholar 

  13. Roon KI, Olesen J, Diener HC et al (2000) No acute antimigraine efficacy of CP122288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. Ann Neurol 47: 238–241

    Article  PubMed  CAS  Google Scholar 

  14. Clozel M, Breu V, Gray GA (1994) Pharmacological characterization of bosetan, a new potent orally active non-peptide endothelin receptor antagonist. J Pharmacol Exp Ther 270: 228–235

    PubMed  CAS  Google Scholar 

  15. Brändli P, Löffler BM, Breu V et al (1996) Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 64: 315–322

    Article  PubMed  Google Scholar 

  16. May A, Gijsman HJ, Wallnöfer et al (1996) Endothelin antagonist bosetan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 67: 375–378

    Article  PubMed  CAS  Google Scholar 

  17. Smith MI, Read SJ, Chan WN et al (2000) Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia 20: 546–553

    Article  PubMed  CAS  Google Scholar 

  18. Maassen van den Brink A, Van den Broek RWM, De Vries R et al (2000) The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia 20: 538–545

    Article  Google Scholar 

  19. Moussaoui SM, Garret C (1997) Are substance P antagonists potential treatment for migraine and related headaches, pain, and emesis? In: J Olesen, P Tfelt-Hansen (eds): Headache treatment: trial methodology and new drugs. Lippincott-Raven Publishers, Philadelphia, 303–311

    Google Scholar 

  20. Lee WS, Moussaoui S, Moskowitz MA (1994) Blockade of oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva. Br J Pharmacol 112: 920–924

    Article  PubMed  CAS  Google Scholar 

  21. Phebus LA, Johnson KW, Stengel PW et al (1997) The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life Sciences 60: 1553–1561

    Article  PubMed  CAS  Google Scholar 

  22. Goldstein DJ, Wang O, Saper JR et al (1997) Ineffectiveness of neurokinin-1 antagonists in acute migraine: a crossover study. Cephalalgia 17: 785–790

    Article  PubMed  CAS  Google Scholar 

  23. Newby DE, Sciberras DG, Ferro CJ et al (1999) Substance P-induced vasodilation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man. Br J Clin Pharmacol 48: 336–344

    Article  PubMed  CAS  Google Scholar 

  24. Norman B, Panebianco D, Block GA (1998) A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine (abstract). Cephalalgia 18: 407

    Google Scholar 

  25. Polley JS, Gaskin PJ, Perren MJ et al (1997) The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system. Regulatory Peptides 68: 23–29

    Article  PubMed  CAS  Google Scholar 

  26. Connor HE, Bertin L, Gillies S et al (1998) Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine (abstract). Cephalalgia 18: 392

    Google Scholar 

  27. Doods H, Hallermayer G, Wu D et al (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129: 420–423

    Article  PubMed  CAS  Google Scholar 

  28. Goldstein DJ, Offen WW, Klein EG, Phebus LA (1999) Lanepitant, an NK-1 antagonist, in migraine prophylaxis (abstract). Cephalalgia 19: 377

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA

    Egilius L. H. Spierings

Authors
  1. Egilius L. H. Spierings
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA

    Egilius L. H. Spierings

  2. Headache Unit, Department of Neurology, Fundación Hospital Alcorcón Juan Carlos I University, Madrid, Spain

    Margarita Sánchez del Río

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Basel AG

About this chapter

Cite this chapter

Spierings, E.L.H. (2002). Inhibition of neurogenic inflammation in abortive migraine treatment. In: Spierings, E.L.H., Sánchez del Río, M. (eds) Migraine: A Neuroinflammatory Disease?. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8131-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8131-9_8

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9449-4

  • Online ISBN: 978-3-0348-8131-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation